Objectives: Levofloxacin has a high bioavailability and a broad antibacterial spectrum which covers the common pathogens found in acute and chronic diabetic foot infections. The purpose of our study was to determine the serum and tissue concentrations of levofloxacin when administered orally in patients with infected diabetic foot ulcers and to compare these values with microbiological findings.
Introduction
In antibiotic therapy, it is important to achieve effective local tissue concentration at the infected site. In diabetic foot infection (a lesion with reduced blood flow), this is particularly difficult to achieve and the diabetic foot syndrome represents a special and complex problem among late diabetic complications. Currently 4%-7% of diabetic patients develop a diabetic foot syndrome at some time after the diagnosis of diabetes. 1 For these patients, polymicrobial skin structure infections caused by reduced immune reactivity combined with functional disturbance of microcirculation are frequently seen following small injuries. 2 Thus, when initiating treatment an antimicrobial agent should be chosen which achieves good penetration into the site of this difficult-to-treat infection.
Levofloxacin, a fluoroquinolone with high bioavailability and extended half-life, has a broad antibacterial spectrum including enterobacteria, non-fermenters and Gram-positive cocci. 3 Members of these species are common pathogens in acute and chronic diabetic foot infections and therefore levofloxacin may be a suitable agent in the therapy of diabetic outpatients. To date, there are no data on levofloxacin concentrations in infected necrotic tissue in diabetic patients. The purpose of our study was to determine serum and tissue concentrations of levofloxacin following the oral administration of 500 mg, for at least 6 days, to patients with infected diabetic foot ulcers, and to correlate these values with microbiological findings.
Materials and methods

Patients
The protocol was approved by the Ethics Committee of the University of Heidelberg, Germany. All patients were required to give written informed consent. Patients with open ulcers of the lower limbs resulting from underlying diabetes were considered suitable for the study. All patients had lesions of Wagner grade 2 (deep ulcer/wound penetrating to tendon, bone or joint with infection in the surrounding soft tissue) 4 and were treated in an outpatient setting. Exclusion criteria were (i) administration of another fluoroquinolone within 7 days before surgery, (ii) known allergy to fluoroquinolones, (iii) end-stage renal disease, (iv) pregnancy or lactation, (v) co-administration of probenecid, cimetidine or ferrotherapy. During the initial examination of the patient, debridement was performed and a wound swab taken from the base of the infected ulcer. A control examination was carried out after at least 6 days. Blood and tissue samples (second debridement) were taken. The excised tissue was used for a microbiological follow-up culture as well as for levofloxacin analysis.
Drug administration
All patients received levofloxacin orally at a dose of 500 mg once daily following the initial examination. Levofloxacin was given for 10 ± 3.8 days before the second debridement. The patients received no other antimicrobial agents and no other known oral medications that could interact with levofloxacin (sucralfate, theophylline, fenbufen, antacids, magnesium).
Blood and tissue sampling
Blood samples were collected in serum tubes simultaneously with wound tissue debridement. Serum was separated by centrifugation (2772g, 10 min) and stored at À258C until analysis. Tissue specimens were wiped gently with dry gauze and immediately stored at À258C until analysis.
Analytical method
Levofloxacin was determined by high performance liquid chromatography (HPLC) with fluorimetric detection as described by Boettcher et al. 5, 6 Briefly, tissue and serum samples spiked with the internal standard ciprofloxacin were prepared by protein precipitation with perchloric and phosphoric acid and methanol; tissue samples were homogenized with an Ultra Turrax dispenser. The compounds were separated on a reversed-phase column with an acid mobile phase containing triethylamine (water, methanol, triethylamine and ortho-phosphoric acid, 750/250/4/2.5, by vol., pH 3). The HPLC assay was linear over the usable concentration range (0.1-40 mg/L). The limit of quantification was determined as 0.01 mg/L, the limit of detection was 0.001 mg/L. The intra-and interday coefficients of variation were <5%.
Microbiology
All wound swabs and tissues were transferred to a microbiology laboratory and cultured aerobically and anaerobically. Culture, isolation and identification of the bacteria were performed according to standardized techniques. Susceptibility testing was performed using the microdilution method (break points according to NCCLS). The exact MICs for levofloxacin were determined using the Etest (VIVA, Hürth, Germany).
Results
Levofloxacin concentrations
Initially, 11 patients were enrolled in the study (six men, five women). One patient was withdrawn because of non-compliance. Evaluable patients included five men and five women with a mean age of 62.8 years. Seven patients were classified as having type 2 diabetes and two as type 1 (one unclassified). Diabetes was controlled by insulin in seven patients. The patients had a mean HbA 1c of 6.82% (median 6.9%, range, 4.3% -7.6%) and an average serum creatinine of 1. Table 1 ). The levofloxacin concentrations in wound tissue were between 2.33 -23.23 mg/kg. Concentrations in tissue were higher compared with serum in all patients (Table 1) . There was no correlation or trend between tissue concentration of levofloxacin 
Microbiology
A microbiological swab was obtained from nine out of 10 patients before levofloxacin therapy. At least one potential pathogen was isolated from each of these nine patients (Table 2) . Coagulase-negative staphylococci and corynebacteria were regarded as skin flora and non-pathogens. After levofloxacin therapy of 6-15 days the causal pathogen persisted in two patients (case D1 and D2). In one patient (case D11), a new pathogen (levofloxacin resistant) was isolated and in seven patients (cases D3-D10) no pathogen was found following treatment. In terms of the pharmacokinetic -pharmacodynamic correlation, the ratio between levofloxacin concentrations in wound tissue and the MIC of the causal pathogen was calculated. This ratio was in the range >1.2 -82.2 for the pathogens isolated before levofloxacin therapy. In total, six of the nine patients with positive findings at the initial examination achieved microbiological cure.
Discussion
Levofloxacin showed excellent penetration into the wound tissue of the diabetic foot ulcers treated in this study, achieving concentrations, well in excess of those found in serum. These tissue concentrations were similar to those reported for ofloxacin in necrotic foot lesions of diabetic and non-diabetic patients with peripheral arterial occlusive disease. 7, 8 Chow et al. 9 examined skin tissue of healthy volunteers with a dose of 750 mg levofloxacin once daily for 3 days. He found the highest concentration of levofloxacin 6 h after administration of the dose, with a mean concentration of 11.87 ± 2.58 mg/kg. Our results for wound tissue in diabetic patients treated with 500 mg of levofloxacin, at 10.78 ± 6.48 mg/kg, were similar to the figures reported by Chow et al. 9 However, unlike Chow and colleagues, at steady state, after at least 6 days of oral therapy with levofloxacin, we did not find a correlation between tissue concentration of levofloxacin and time from last dose to sampling (Table 1) .
In this study, a variety of pathogens were isolated, including multi-resistant and non-fermenting bacteria. Microbiological follow-up cultures showed that in seven out of nine patients (78%) the pathogens initially isolated could be eradicated, although in a further patient, infection with a different organism occurred (Table 2) . Our results are similar to those reported by Lipsky et al. 10 who found that 78% of diabetic foot infections responded satisfactorily to a parenteral-to oral regimen of ofloxacin. A slightly higher microbiological eradication rate (83.4%) was reported by Graham et al.
11 using 750 mg levofloxacin once daily for treatment of complicated skin structure infections in a larger study with 98 patients evaluable for microbiological efficacy.
In two cases, we found no change in isolated bacteria (in both cases the bacteria isolated before and after treatment were susceptible to levofloxacin). In one case, a methicillin-susceptible but levofloxacin-resistant Staphylococcus aureus was cultured following treatment. The tissue concentrations in these three patients were high (7.73, 9.66 and 14.14 mg/kg) and there did not appear to be a relationship between concentration and outcome. In 50% of our patients (D2, D6, D8, D10 and D11), fluoroquinolones were one of the few oral monotherapy options where the spectrum covered all of the isolated pathogens. Levofloxacin exhibits an adequate spectrum for the empirical treatment of diabetic foot ulcer. However, during focused therapy in the other 50% of our patients there would have been the possibility to use narrower-spectrum and less expensive agents. In a recent publication, therapy with fluoroquinolones was found to be a significant risk factor in the acquisition of methicillin-resistant S. aureus (MRSA) by hospitalized patients. 12 The authors of this study suggested that the eradication of susceptible microorganisms normally colonizing the skin and mucous membranes effectively opens an ecological niche and in doing so, renders a patient vulnerable to colonization by resistant strains endemic in the hospital, including MRSA. For this mechanism to succeed, MRSA needs to be present in the environment ready to colonize the patient given the opportunity. If this is correct, it is unlikely that the mechanism also operates in a setting with lower MRSA prevalence in patients and lower MRSA contamination in the environment. At present, there are no data to suggest that where the prevalence of MRSA is low, fluoroquinolone use for therapy of diabetic foot infection constitutes an increased risk for MRSA acquisition. In conclusion, we have shown that levofloxacin reaches high concentrations in infected and necrotic wound tissue of diabetic foot ulcers. In combination with adequate surgical debridement, levofloxacin seems well suited to the treatment of skin structure infections of diabetics, caused by susceptible organisms.
